 |
|
|
|||||
Indian pharma stocks are rebounding, driven by domestic investors after a period of Foreign Institutional Investor (FII) selling pressure. Uncertainty surrounding potential US tariffs, fueled by Trump's statements and delays in the Bilateral Trade Agreement (BTA), had initially impacted the sector. While FIIs remain cautious, positive earnings reports and the defensive nature of domestic-oriented pharma businesses are attracting DII interest.
Category:
News and Media
India's corporate bond market is attracting retail investors due to SEBI's reforms like reduced ticket sizes and enhanced transparency. As traditional instruments become less appealing, investors are exploring corporate bonds for better yields and diversification. Anticipated rate cuts are expected to further boost corporate bond issuance, particularly in short-term bonds, driven by rate cut anticipation and liquidity infusion.
Category:
News and Media
India's primary market anticipates a $50 billion IPO surge in the next 12-18 months, driven by private equity exits and corporate fundraising. While this signals economic confidence, concerns arise regarding valuation sustainability and market absorption capacity. Investor selectivity and robust earnings delivery will be crucial for navigating this influx of new offerings.
Category:
News and Media
All news |
||||||||||||||||||
|
||||||||||||||||||